Infectious Diseases (all articles)
CoronaVac study in Brazil: Is the vaccine 50%, 78%, or 100% effective?
14 Jan, 2021 | 02:11h | UTCThird time’s the charm? Brazil scales back efficacy claims for COVID-19 vaccine from China – Science
See also: CoronaVac’s Overall Efficacy in Brazil Measured at 50.4% – Bloomberg
Meta-analysis: Saliva vs. nasopharyngeal swabs equally sensitive for Covid-19 diagnosis
14 Jan, 2021 | 02:13h | UTCCommentary: Saliva, Nasopharyngeal Samples Equally Sensitive for SARS-CoV-2 – Physician’s Weekly
Commentary on Twitter
https://twitter.com/EricTopol/status/1348758183846703104
A guide to vaccinology: from basic principles to new developments
14 Jan, 2021 | 02:09h | UTCA guide to vaccinology: from basic principles to new developments – Nature Reviews Immunology
Pragmatic Recommendations for the Management of COVID-19 in Low- and Middle-Income Countries
14 Jan, 2021 | 02:04h | UTC- Editorial: Recommendations for the Management of COVID-19 in Low- and Middle-Income Countries – The American Journal of Tropical Medicine and Hygiene
- Pragmatic Recommendations for the Management of Acute Respiratory Failure and Mechanical Ventilation in Patients with COVID-19 in Low- and Middle-Income Countries – The American Journal of Tropical Medicine and Hygiene
- Pragmatic Recommendations for the Management of Anticoagulation and Venous Thrombotic Disease for Hospitalized Patients with COVID-19 in Low- and Middle-Income Countries – The American Journal of Tropical Medicine and Hygiene
- Pragmatic Recommendations for Identification and Triage of Patients with COVID-19 Disease in Low- and Middle-Income Countries – The American Journal of Tropical Medicine and Hygiene
- Pragmatic Recommendations for Tracheostomy, Discharge, and Rehabilitation Measures in Hospitalized Patients Recovering From Severe COVID-19 in Low- and Middle-Income Countries – The American Journal of Tropical Medicine and Hygiene
- Pragmatic Recommendations for the Prevention and Treatment of Acute Kidney Injury in Patients with COVID-19 in Low- and Middle-Income Countries – The American Journal of Tropical Medicine and Hygiene
- Pragmatic Recommendations for Infection Prevention and Control Practices for Healthcare Facilities in Low- and Middle-Income Countries during the COVID-19 Pandemic – Journal of Tropical Medicine and Hygiene
How COVID unlocked the power of RNA vaccines
14 Jan, 2021 | 02:09h | UTCHow COVID unlocked the power of RNA vaccines – Nature
Commentary: RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics? – Frontiers in Immunology
Three studies highlight low COVID risk of in-person school
14 Jan, 2021 | 02:06h | UTCThree studies highlight low COVID risk of in-person school – CIDRAP
Study 1: Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden – New England Journal of Medicine
Study 2: Incidence and Secondary Transmission of SARS-CoV-2 Infections in Schools – Pediatrics
No ICU beds? Expect double the number of Covid-19 deaths
14 Jan, 2021 | 02:05h | UTCNo ICU beds? Expect double the number of Covid-19 deaths. – Vox
Study estimates 50% of new SARS-CoV-2 infections have originated from exposure to asymptomatic or pre-symptomatic individuals
14 Jan, 2021 | 02:08h | UTCSARS-CoV-2 Transmission From People Without COVID-19 Symptoms – JAMA Network Open
Commentary: At least 50% of COVID-19 cases spread from people without symptoms, a new study found – Business Insider AND More than half of Covid-19 infections acquired from asymptomatic carriers – MedicalResearch
Commentary on Twitter
https://twitter.com/TennantRuth/status/1348208811039985665
Preparing previously COVID-19-positive patients for elective surgery: A framework for preoperative evaluation
14 Jan, 2021 | 02:02h | UTC
Antibiotics alone for uncomplicated appendicitis: Oral Moxifloxacin almost as good as intravenous Ertapenem + oral Levofloxacin
14 Jan, 2021 | 01:57h | UTCEditorial: Evolving Issues in the Use of Antibiotics for the Treatment of Uncomplicated Appendicitis
Commentary: More Support for Single-Drug Antibiotics for Uncomplicated Appendicitis – Physician’s Weekly
Commentary on Twitter
In this RCT comparing 7d oral moxifloxacin vs 2d IV ertapenam 5d oral levofloxacin metronidazole for adults w uncomplicated #appendicitis, Tx success was >65% for both, but oral #antibiotics did not meet noninferiority criteria vs IV PO https://t.co/SwcopsGZTm #VisualAbstract
— JAMA (@JAMA_current) January 12, 2021
Global, regional, and national dengue burden from 1990 to 2017: A systematic analysis based on the global burden of disease study 2017
14 Jan, 2021 | 01:48h | UTC
Immunogenicity and safety of fractional doses of yellow fever vaccines: A randomized, double-blind, non-inferiority trial
14 Jan, 2021 | 01:38h | UTCInvited commentary: Public health role for fractional dosage of yellow fever vaccine – The Lancet
Short review: How Dangerous are new COVID-19 strains?
13 Jan, 2021 | 02:31h | UTCHow Dangerous Are New COVID-19 Strains? – Council on Foreign Relations
Commentary on Twitter
How dangerous are the B.1.1.7 and 501Y.V2 hyper-transmissible strains?
by @AdamJKucharski @CFR_orghttps://t.co/aycWMN3b5h
h/t @Karl_Lauterbach pic.twitter.com/JlaFzzP06t— Eric Topol (@EricTopol) January 11, 2021
Confirmed reinfection with SARS-CoV-2 variant VOC-202012/01
13 Jan, 2021 | 02:30h | UTCConfirmed Reinfection with SARS-CoV-2 Variant VOC-202012/01 – Clinical Infectious Diseases
Commentary on Twitter
A new case report of reinfection with SARS-CoV-2 with the second episode due to the ‘new variant’ VOC-202012/01 of lineage B.1.1.7. The initial infection was mild illness while the second infection caused severe and critical illness. @InfectiousDz #CID https://t.co/hhP3gUnQSZ
— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) January 9, 2021
Masks and face coverings for the lay public: A narrative update
13 Jan, 2021 | 02:23h | UTCMasks and Face Coverings for the Lay Public: A Narrative Update – Annals of Internal Medicine
Commentary on Twitter (thread – click for more)
Masks work.
A new and comprehensive update from @trishgreenhalgh
et al."Evidence that the virus can be airborne (and therefore be inhaled) and that masking policies, when effectively delivered, save lives is now strong."https://t.co/Tl9VrmPNlW pic.twitter.com/zfuV774jyN
— Laura McCall #NoMassInfection (@equibotanica) December 29, 2020
Six RCTs to answer one question: what is the role of tocilizumab in COVID-19?
13 Jan, 2021 | 02:28h | UTCSix RCTs to answer one question: what is the role of tocilizumab in COVID-19? – PulmCrit
Related (study and commentaries): Randomized trial: Arthritis drugs improve survival in critically ill patients with Covid-19
Video (3 min): Which Covid vaccine is better? Pfizer v Oxford v Moderna
13 Jan, 2021 | 02:21h | UTCWhich Covid vaccine is better? Pfizer v Oxford v Moderna – BBC
An evidence review of face masks against COVID-19
13 Jan, 2021 | 02:26h | UTCAn evidence review of face masks against COVID-19 – Proceedings of the National Academy of Sciences
Commentary on Twitter
https://mobile.twitter.com/jeremyphoward/status/1348771993949151232
Loss of smell in mild Covid-19 cases occurs 86% of the time, study says
13 Jan, 2021 | 02:20h | UTCLoss of smell in mild Covid-19 cases occurs 86% of the time, study says – CNN
Original study: Prevalence and 6‐month recovery of olfactory dysfunction: a multicentre study of 1363 COVID‐19 patients – Journal of Internal Medicine
Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response
13 Jan, 2021 | 02:10h | UTC
Commentaries on Twitter
New paper via our PREVENT Group w 22 concrete recs that provide a roadmap for the ethically responsible, socially just, & respectful inclusion of the interests of pregnant women in the development & deployment of vaccines against emerging pathogens. https://t.co/tp6gt20dh0
— Ruth Faden (@fadenethx) May 6, 2019
Infectious disease outbreaks can severely affect the health interests of pregnant women and their babies. PREVENT's guidance promotes the inclusion of pregnant women in the development and deployment of vaccines against emerging pathogens ➡️ https://t.co/P8IKXCU8tI pic.twitter.com/LYDHfQ2f9y
— CEPI (@CEPIvaccines) May 13, 2019
Inferring the effectiveness of government interventions against COVID-19
13 Jan, 2021 | 02:17h | UTCInferring the effectiveness of government interventions against COVID-19 – Science
Commentary on Twitter
Do we really need #StayAtHome orders?
New @ScienceMagazine modeling explores what really works around the globe.
TL;DR: the answer is no. Targeted efforts work; the effect of stay at home is small👍https://t.co/Km7kfWyVUJ by @JanMBrauner @jankulveitb @OATML_Oxford @fhioxford pic.twitter.com/Uo0lhZD5WR— Eric Topol (@EricTopol) December 15, 2020
Covid-19: Breastfeeding women can have vaccine after guidance turnaround
13 Jan, 2021 | 02:11h | UTCCovid-19: Breastfeeding women can have vaccine after guidance turnaround – The BMJ
Related opinion: Why were breastfeeding women denied the covid-19 vaccine? – The BMJ
USPSTF recommends screening for Hepatitis B Virus infection in adolescents and adults
13 Jan, 2021 | 01:43h | UTCAuthor Interview: USPSTF Recommendation: Screening for Hepatitis B Virus Infection in Adolescents and Adults
Patient Page: Screening for Hepatitis B in Nonpregnant Adolescents and Adults – JAMA
Blood plasma treatment has limited effect for sickest COVID-19 patients
12 Jan, 2021 | 02:07h | UTCBlood plasma treatment has limited effect for sickest COVID-19 patients – Imperial College London
See also: Expert reaction to REMAP-CAP recruitment of severely ill COVID-19 patients into convalescent plasma trial being paused after initial analysis suggested it did not improve outcomes – Science Media Centre AND Trial of COVID-19 blood plasma finds no benefit in severely ill patients – Reuters
Randomized trial: Plasma therapy administered early is beneficial in high-risk elderly patients
12 Jan, 2021 | 02:05h | UTCCommentaries: Early convalescent plasma may lower risk of severe COVID in seniors – CIDRAP AND Covid-19: Early Plasma Treatment Improved Outcomes in Older Patients – Physician’s Weekly
Commentaries on Twitter
Just published @NEJM: A small, placebo-controlled randomized trial (N=160) of high IgG titer convalescent plasma administered early (within 72 hrs) for mild covid-19 to older adults (median age >70) shows benefit https://t.co/dhyFH4OwpH pic.twitter.com/14lMBBofUh
— Eric Topol (@EricTopol) January 6, 2021
Early convalescent plasma may lower risk of severe COVID in seniors@NEJM study finds that 16% of those treated with high-titer convalescent therapy developed severe #COVID19, compared with 31% in the placebo grouphttps://t.co/7hqCXsNHDM pic.twitter.com/dZDUwcjxUh
— CIDRAP (@CIDRAP) January 6, 2021